One-Year Data Show Golimumab Improved Signs And Symptoms In Patients With Psoriatic Arthritis In Phase 3 Study

More than half of patients receiving every four week subcutaneous injections of golimumab (CNTO 148) 50 mg and 100 mg, an investigational therapy, experienced sustained improvements in the joint and skin symptoms of active psoriatic arthritis through six months with results sustained through one year.